Novavax, COVID-19 and mRNA vaccine
Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...
Novavax’s vaccine is based on protein technology, which takes longer to manufacture than mRNA vaccines like those made by Pfizer and BioNTech and Moderna. Protein-based vaccines work by getting ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in ...
Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.
Novavax occupies five sites in Montgomery County totaling about 370,000 square feet. Its footprint includes its headquarters ...
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...